AbbVie Inc (ABBV)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Richard A. Gonzalez
Employees:
50,000
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL 60064
(847) 932-7900

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh├žet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

Data derived from most recent annual or quarterly report
Market Cap 258.373 Billion Shares Outstanding1.766 Billion Avg 30-day Volume 5.801 Million
P/E Ratio17.5995 Dividend Yield4.1623 EPS1.3
Price to Revenue4.0809 Debt to Equity4.343 EBITDA25.211 Billion
Price to Book Value14.7528 Operating Margin30.593700000000002 Enterprise Value293.481 Billion
Current Ratio0.928 EPS Growth0.845 Quick Ratio0.692
1 Yr BETA 0.3483 52-week High/Low 169.46 / 128.17 Profit Margin23.2069
Operating Cash Flow Growth0.1507 Altman Z-Score1.9633 Free Cash Flow to Firm 24.314 Billion
View SEC Filings from ABBV instead.

View recent insider trading info

Funds Holding ABBV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ABBV

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-10-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-29:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-29:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    42.4 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    42.4 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RAPP EDWARD J

    • Director
    23,256 2022-12-31 5

    ALPERN ROBERT J

    • Director
    8,723 2022-12-31 5

    RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER

    • Officer
    13,837 2022-12-12 3

    SIATIS PERRY C EVP, GC AND SECRETARY

    • Officer
    10,377 2022-10-17 1

    REENTS SCOTT T SVP, CHIEF FINANCIAL OFFICER

    • Officer
    809 2022-06-28 1

    SEVERINO MICHAEL VICE CHAIRMAN

    • Officer
    233,769 2022-05-23 5

    GOSEBRUCH HENRY O EVP, CHIEF STRATEGY OFFICER

    • Officer
    98,580 2022-05-16 6

    STROM CARRIE C SVP & PRES GLOBAL ALLERG AESTH

    • Officer
    40,663 2022-05-11 7

    AUSTIN ROXANNE S

    • Director
    50,705 2022-05-06 1

    TILTON GLENN F

    • Director
    47,939 2022-05-06 1

    WADDELL FREDERICK H

    • Director
    24,983 2022-05-06 1

    FREYMAN THOMAS C

    • Director
    128,717 2022-05-06 1

    ROBERTS REBECCA B

    • Director
    9,753 2022-05-06 1

    HART BRETT J

    • Director
    15,497 2022-05-06 1

    BURNSIDE WILLIAM H.L.

    • Director
    22,983 2022-05-06 1

    MEYER MELODY B

    • Director
    12,523 2022-05-06 1

    LIDDY EDWARD M

    • Director
    28,474 2022-03-31 1

    STEWART JEFFREY RYAN EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    62,279 2022-03-24 3

    DURKIN BRIAN L VP, CONTROLLER

    • Officer
    19,094 2022-03-09 3

    GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO

    • Officer
    • Director
    526,768 2022-02-25 2

    SCHUMACHER LAURA J VICE CHAIRMAN

    • Officer
    248,002 2022-02-25 2

    SALEKI-GERHARDT AZITA EVP, OPERATIONS

    • Officer
    164,107 2022-02-25 2

    MICHAEL ROBERT A. VICE CHAIRMAN

    • Officer
    37,877 2022-02-25 2

    HUDSON THOMAS J SVP, R&D AND CSO

    • Officer
    46,228 2022-02-25 2

    SORG ELAINE K. SVP, US COMMERCIAL OPERATIONS

    • Officer
    17,876 2022-02-25 2

    ALBAN CARLOS VICE CHAIRMAN

    • Officer
    155,341 2020-11-16 0

    DONOGHOE NICHOLAS SVP, ENTERPRISE INNOVATION

    • Officer
    15,149 2020-02-28 0

    CHASE WILLIAM J EVP, FINANCE & ADMINISTRATION

    • Officer
    170,053 2019-06-26 0

    HURWICH THOMAS A. VP, CONTROLLER

    • Officer
    No longer subject to file 2017-02-28 0

    ROBERTS ROY S

    • Director
    27,486 2015-05-08 0

    LEONARD JOHN M. SVP, CHIEF SCIENTIFIC OFFICER

    • Officer
    113,793 2013-03-15 0

    ABBOTT LABORATORIES

    • 10% Owner
    0 2012-12-12 0

    LINDER GREG W

    • Director
    0 2012-12-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    RAPP EDWARD J - Director

    2023-01-03 17:05:16 -0500 2022-12-31 A 239 $161.61 a 23,256 direct

    ALPERN ROBERT J - Director

    2023-01-03 17:06:24 -0500 2022-12-31 A 46 $161.61 a 8,723 direct

    RICHMOND TIMOTHY J. - Officer EVP, CHIEF HR OFFICER

    2022-12-14 17:06:08 -0500 2022-12-12 M 42,370 $54.86 a 56,207 direct -1.6064 0.1042 0.1042 6 -1.6064 2

    RICHMOND TIMOTHY J. - Officer EVP, CHIEF HR OFFICER

    2022-12-14 17:06:08 -0500 2022-12-12 S 39,295 $163.39 d 16,912 direct yes -1.6064 0.1042 0.1042 6 -1.6064 2

    RICHMOND TIMOTHY J. - Officer EVP, CHIEF HR OFFICER

    2022-12-14 17:06:08 -0500 2022-12-12 S 3,075 $164.10 d 13,837 direct yes -1.6064 0.1042 0.1042 6 -1.6064 2

    RICHMOND TIMOTHY J. - Officer EVP, CHIEF HR OFFICER

    2022-12-14 17:06:08 -0500 2022-12-12 M 42,370 d 0 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ABBVIE INC ABBV 2023-01-27 22:15:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 21:45:04 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 21:15:04 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 20:45:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 20:15:04 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 19:45:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 19:15:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 18:45:04 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 18:15:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 17:45:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 17:15:04 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 16:45:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 16:15:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 15:45:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 15:15:04 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 14:45:04 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 14:15:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 13:45:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 13:15:03 UTC 4.07 0.25 0
    ABBVIE INC ABBV 2023-01-27 12:45:03 UTC 4.07 0.25 0

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Highland Funds I- Highland Long/Short Equity Fund ABBV -6763.0 shares, $-515272.97 2020-03-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund ABBV -37.0 shares, $-3240.83 2020-09-30 N-PORT
    VIVALDI OPPORTUNITIES FUND- Vivaldi Opportunities Fund ABBV -10598.0 shares, $-807461.62 2020-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ABBV -700.0 shares, $-93947.0 2022-09-30 N-PORT
    GMO TRUST- GMO Benchmark-Free Fund ABBV -300.0 shares, $-48354.0 2022-11-30 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Rohit Khanna democrat House Filing 2022-12-02 2022-11-03 SP P $1,001-$15,000
    Hon. Rohit Khanna democrat House Filing 2022-11-02 2022-10-20 DC S $1,001-$15,000
    Hon. Rohit Khanna democrat House Filing 2022-11-02 2022-10-20 DC SP $1,001-$15,000
    Hon. Rohit Khanna democrat House Filing 2022-11-02 2022-10-20 SP S $1,001-$15,000
    Hon. Kathy Manning democrat House Filing 2022-10-04 2022-09-12 SP P $1,001-$15,000
    representative Rohit Khanna democrat House Filing 2022-09-08 2022-08-23 SP SP $1,001-$15,000
    representative Dwight Evans democrat House Filing 2022-08-16 2022-08-05 P $1,001-$15,000
    representative Kathy Manning democrat House Filing 2022-08-03 2022-07-27 SP SP $1,001-$15,000
    representative Kathy Manning democrat House Filing 2022-08-02 2022-07-15 SP P $1,001-$15,000
    representative Kathy Manning democrat House Filing 2022-08-02 2022-07-27 SP P $1,001-$15,000
    representative Kathy Manning democrat House Filing 2022-08-02 2022-07-27 SP $15,001-$50,000

    Elevate your investments